Pancreatic cancer is a highly deadly disease: almost all patients develop metastases and
conventional treatments have little impact on survival. Therapeutically, this tumor is poorly …

The mTOR pathway was discovered in the late 1970s after the compound and natural
inhibitor of mTOR, rapamycin was isolated from the bacterium Streptomyces hygroscopicus …

Cancer cell metabolism including aerobic glycolysis, amino acid and fatty acid metabolism,
has been extensively studied. Metabolic reprogramming is a major hallmark of cancer …

The mechanistic target of rapamycin (mTOR) pathway integrates metabolic cues into cell
fate decisions. A particularly fateful event during the adaptive immune response is the …

Rapamycin is a macrolide antibiotic that functions as an immunosuppressive and anti‐
cancer agent, and displays robust anti‐ageing effects in multiple organisms including …

Meningiomas are the most common primary intracranial adult tumor. All Neurofibromatosis 2
(NF2)-associated meningiomas and~ 60% of sporadic meningiomas show loss of NF2 tumor …

Target of rapamycin (TOR) is a conserved eukaryotic phosphatidylinositol 3-kinase-related
kinase that regulates growth and metabolism in response to environment in plants and …

Ciclopirox olamine (CPX), an off-patent fungicide, has recently been identified as a novel
anticancer agent. However, the molecular mechanism underlying its anticancer action …

Meningiomas (MNs), arising from the arachnoid/meningeal layer, are nonresponsive to
chemotherapies, with∼ 50% showing loss of the Neurofibromatosis 2 (NF2) tumor …

As a critical regulator of cell growth, the mechanistic target of rapamycin (mTOR) protein
operates as part of two molecularly and functionally distinct complexes. Herein, we …